High prevalence of pharmacologically induced XXXX in the acute setting of @entity1545 .

@entity1 @entity1545 @entity131 @entity510 @entity1423 @entity117 @entity857 @entity1779
BACKGROUND: The management of @entity1 with @entity131 ( @entity131 ), primary @entity1779 (pICH) and primary @entity510 (pSAH) remains a highly demanding challenge in critical care medicine. Antithrombotic agents are one of the most relevant risk factors for poor outcome. However, in the acute setting of @entity1545 , information on preexisting medication might not be available. This group of @entity1 is insufficiently characterized regarding pharmacologically induced @entity1423 . METHODS: We retrospectively analyzed consecutive @entity1 with @entity131 , pICH and pSAH admitted to our department with unknown preexisting medication. The impact of @entity117 and @entity857 -receptor antagonists on platelet function was tested via the Multiplate analyzer. @entity1 ' characteristics, management and the influence of @entity1423 on outcome were evaluated. RESULTS: Within 25  months 103 @entity1 with @entity131 (61), pICH (32) or pSAH (10) and unknown antithrombotic medication were admitted to our department. In 54 (52.4  %) of the @entity1 reduced platelet function was detected, mainly caused by @entity117 . In the @entity131 group, 30 @entity1 (49.2  %) were identified, while Multiplate analysis detected @entity1423 in 19 (59.4  %) subjects in the pICH group and 5 in the pSAH group (50  %). In multivariable analysis the pathological Multiplate result was not associated with worse outcome; however, in our cohort 47 (87  %) @entity1 received hemostatic therapy following detection of impaired platelet function. CONCLUSION: Our results demonstrate the high frequency of pharmacologically impaired platelet function in @entity1 with unknown preexisting medication. Early assessment of platelet function is an important tool to allow optimized treatment in these @entity1 .
